

Outpatient Medical Injectable Intra-Articular Hyaluronan Injections Request Form: Fax to 833-581-1861 (Medical Benefit Only)

Member Name:		
Member Date of Birth:		
Member ID (UMI):		Medicare
Ordering/Attending Provider Name:		NPI:
Ordering/Attending Provider Addre	ss:	
Office Contact:	Phone #:	Fax #:
Servicing Facility/Vendor Name:		Facility NPI:
Servicing Facility/Vendor Address:_		
Requested Start Date of Service:	ICD10 Diagnosis Code(s):	
☐ Buy & Bill ☐ Drug Supplied by S	oecialty Pharmacy (Pharmacy Name:	NPI:)
DRUG INFORMATION (please sele		
PREFERRED	NON-PREFERRED**	
PRODUCTS	Synvisc (J7325)	GenVisc 850 (J7320)
	Synvisc-One (J7325)	☐ Hymovis (J7322)
These products DO	☐ Monovisc (J7327)	☐ Synojoynt (J7331)
NOT require	☐ Gel One (J7326)	☐ Triluron (J7332)
<u>authorization</u>	☐ Hyalgan (J7321)	☐ Visco-3 (J7321)
	Orthovisc (J7324)	☐ TriVisc (J7329)
Euflexxa (J7323)	**A non-preferred product may be considered medically necessary if the member has experienced a documented drug therapy failure (after an adequate trial), intolerance, or contraindication to ALL preferred products.	
☐ Supartz (J7321)		
☐ GelSyn-3 (J7328)		on a non-preferred therapy are not required to try a
☐ Durolane (J7318)	preferred option	, , , , , , , , , , , , , , , , , , , ,
	**Please specify if the member has tried and failed the following: (Answer below)	
	Euflexxa (J7323) 🔲 Yes (Date:) 🛘 No
	Supartz (J7321))
	GelSyn-3 (J7328)) 🔲 No
	Durolane (J7318)) 🗆 No
	Please provide clinical rationale for rec	uesting a non-preferred product for this member:

 $[\]ensuremath{^{**}\text{Please}}$ verify member's eligibility and benefits through the health plan $\ensuremath{^{**}}$

CLINICAL INFORMATION			
Does the member have a diagnosis of symptomatic painful osteoarthritis of the knee with no evidence of inflammatory arthritis? YES NO			
Has the member failed to respond adequately to <u>at least 3 months</u> of conservative therapy as defined by the following:			
 Activity modification, participation in a home exercise program implemented by a physical therapist, protective weight bearing. ☐ YES ☐ NO 			
 Non-narcotic analgesics (e.g., acetaminophen, NSAIDS) at Food and Drug Administration (FDA) or compendia based recommended therapeutic doses for osteoarthritis of the knee for a period of time adequate to assess therapeutic benefit, topical external analgesic preparations including capsaicin cream applied to affected knee joint, topical anti-inflammatory preparations applied to affected knee joint. □ YES □ NO 			
■ Intra-articular corticosteroid injections. □ YES □ NO			
Is the member unable to tolerate conservative therapy due to adverse side effects or other medical conditions? \Box YES \Box NO			
Can cause of pain be attributed to other forms of joint disease other than osteoarthritis? \square YES \square NO			
Will the injections be performed by a licensed medical professional (e.g., MD, DO, PA or CRNP)? ☐ YES ☐ NO			
Does the member have any contraindications to hyaluronan injections? YES explain: NO			
☐ New Start	Date of last series:		
	Has the member and provider elected to continue conservative/non-surgical management of the osteoarthritis (no surgery planned within six (6) months of viscosupplementation therapy) ☐ YES ☐ NO		
	Is there a documented reduction in the dose of analgesics or anti-inflammatory medications in the three (3) month period following the injection series (NOTE: not required if the member requires these medications for a comorbid medical condition in addition to knee osteoarthritis) YES NO		
	Is there a documented significant improvement in pain and functional capacity of the knee joint. (ex: an improvement in an objective measurement of pain and/or functional status VAS, WOMAC Index, or other validated objective measure) YES NO		
Please attach all pertinent clinical information			
	Attached: YES NO		

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.